Ansamitocin P3CAS# 66584-72-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 66584-72-3 | SDF | Download SDF |
| PubChem ID | 146156133.0 | Appearance | Powder |
| Formula | C32H43ClN2O9 | M.Wt | 635.15 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(5S,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate | ||
| SMILES | CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)C)C)C)OC)(NC(=O)O2)O | ||
| Standard InChIKey | OPQNCARIZFLNLF-ZRGLQHGPSA-N | ||
| Standard InChI | InChI=1S/C32H43ClN2O9/c1-17(2)29(37)43-25-15-26(36)35(6)21-13-20(14-22(40-7)27(21)33)12-18(3)10-9-11-24(41-8)32(39)16-23(42-30(38)34-32)19(4)28-31(25,5)44-28/h9-11,13-14,17,19,23-25,28,39H,12,15-16H2,1-8H3,(H,34,38)/t19?,23?,24?,25?,28?,31-,32-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Ansamitocin P3 Dilution Calculator
Ansamitocin P3 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5744 mL | 7.8722 mL | 15.7443 mL | 31.4886 mL | 39.3608 mL |
| 5 mM | 0.3149 mL | 1.5744 mL | 3.1489 mL | 6.2977 mL | 7.8722 mL |
| 10 mM | 0.1574 mL | 0.7872 mL | 1.5744 mL | 3.1489 mL | 3.9361 mL |
| 50 mM | 0.0315 mL | 0.1574 mL | 0.3149 mL | 0.6298 mL | 0.7872 mL |
| 100 mM | 0.0157 mL | 0.0787 mL | 0.1574 mL | 0.3149 mL | 0.3936 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Mexoticin
Catalog No.:BCX1533
CAS No.:18196-00-4
- 31-Norlanostenol
Catalog No.:BCX1532
CAS No.:16910-39-7
- (+)-Dehydroabietic acid
Catalog No.:BCX1531
CAS No.:1231-75-0
- d-Epigalbacin
Catalog No.:BCX1530
CAS No.:84709-25-1
- 4-Vinylphenol
Catalog No.:BCX1529
CAS No.:2628-17-3
- Dihydroactindiolide
Catalog No.:BCX1528
CAS No.:15356-74-8
- Isoescin Ie
Catalog No.:BCX1527
CAS No.:1613506-28-7
- (±)-Dihydrokaempferol
Catalog No.:BCX1526
CAS No.:104486-98-8
- Bitalgenin
Catalog No.:BCX1525
CAS No.:2192-25-8
- Luteolin 7-sulfate
Catalog No.:BCX1524
CAS No.:56857-57-9
- Dahurinol
Catalog No.:BCX1523
CAS No.:38908-87-1
- Acetylseneciphylline N-oxide
Catalog No.:BCX1522
CAS No.:123844-00-8
- Isobutyryl alkannin
Catalog No.:BCX1535
CAS No.:87562-78-5
- Chrysophanol-1-O-β-gentiobioside
Catalog No.:BCX1536
CAS No.:54944-38-6
- Chrysophanol triglucoside
Catalog No.:BCX1537
CAS No.:120181-07-9
- 11-epi-morgroside V
Catalog No.:BCX1538
CAS No.:2146088-12-0
- β-Chamigrenic acid
Catalog No.:BCX1539
CAS No.:1174388-31-8
- Epigalantamine
Catalog No.:BCX1540
CAS No.:1668-85-5
- N-Desmethyl Galanthamine
Catalog No.:BCX1541
CAS No.:41303-74-6
- Anemarrhenasaponin Ia
Catalog No.:BCX1542
CAS No.:221317-02-8
- Momordin IIc
Catalog No.:BCX1543
CAS No.:96990-19-1
- Oleanolic acid -3-O-glucosyl(1-2)xylyl(1-3)glucosiduronic acid
Catalog No.:BCX1544
CAS No.:1447508-78-2
- 7α-Hydroxycholesterol
Catalog No.:BCX1545
CAS No.:566-26-7
- 8-Methyl Chrysophanol
Catalog No.:BCX1546
CAS No.:3300-25-2
Biological evaluation of 9-thioansamitocin P3.[Pubmed:38219484]
Biochem Biophys Res Commun. 2024 Feb 12;696:149483.
Highly cytotoxic maytansine derivatives are widely used in targeted tumor delivery. Structure-activity studies published earlier suggested the C9 carbinol to be a key element necessary to retain the potency. However, in 1984 a patent was published by Takeda in which the synthesis of 9-thioansamitocyn (AP3SH) was described and its activity in xenograft models was shown. In this article we summarize the results of an extended study of the anti-tumor properties of AP3SH. Like other maytansinoids, it induces apoptosis and arrests the cell cycle in the G2/M phase. It is metabolized in liver microsomes predominately by C3A4 isoform and doesn't inhibit any CYP isoforms except CYP3A4 (midazolam, IC50 7.84 muM). No hERG inhibition, CYP induction or mutagenicity in Ames tests were observed. AP3SH demonstrates high antiproliferative activity against 25 tumor cell lines and tumor growth inhibition in U937 xenograft model. Application of AP3SH as a cytotoxic payload in drug delivery system was demonstrated by us earlier.
Ansamitocin P3-Loaded Gold-NanoCage Conjugated with Immune Checkpoint Inhibitor to Enhance Photo-Chemo-Thermal Maturation of Dendritic Cells for Hepatocellular Carcinoma.[Pubmed:34451265]
Polymers (Basel). 2021 Aug 15;13(16):2726.
Immunotherapy is a newly developed method for cancer treatment, but still generates limited response in partial patients for hepatocellular carcinoma (HCC) because the immunity cycle is limited by the tumor microenvironment (TME). Herein, we introduce multifunctional gold nanocages (AuNCs)-based nanocarriers with Ansamitocin P3 (AP3) loaded and anti-PDL1 binding (AP3-AuNCs-anti-PDL1) which can combine photothermal therapy, chemotherapeutic agent-triggered DCs maturation, and checkpoint immunotherapy in one platform. The AP3-AuNCs-anti-PDL1 using Avidin-biotin to bind anti-PDL1 on the surface of AP3-AuNCs showed specifically cellular targeting compared to AuNCs, which can increase the immune responses. The AP3-AuNCs+NIR-10 min exhibited the highly activated DCs maturation with two-fold higher than control+NIR, which can be attributed to the significant release of AP3. The results illustrated the synergistic effect of tumor-associated antigens (TAAs) and controlled AP3 release under near infrared (NIR) in triggering effective DCs maturation. Among them, AP3 release played the more important role than the TAAs under PTT in promoting T-cell activation. These results illustrate the promising potential of AuNCs-based nanocarriers combined with AP3 and the checkpoint inhibitors to strengthen the positive loop of immunity cycle.
